Products
How to Buy
Need pricing information? Get a quote on our products today.
Request a Quote
XSeq™ Research Screening Panel*
RainDance Technologies has collaborated with investigators at Emory University to design the industry’s most comprehensive genetic screening panel for human X-chromosome research. The XSeq™ Research Screening Panel enables scientists to interrogate 802 genes on the X chromosome simultaneously, and in a single assay, using next-generation sequencing (NGS) technology to detect specific known and novel mutations in a cost-effective manner.
Recent studies in human genetics indicate there are more than 800 protein-coding genes on the X chromosome, including many that play key roles in autism and other developmental disorders and intellectual disabilities.1,2 However, current cost and technology constraints make it difficult for researchers to detect many of the important sequence variants associated with these complex disorders. Whole-genome sequencing is expensive and not conducive for routine clinical use; hybridization-based sequence enrichment methods and whole-exome sequencing often lack the required genomic coverage and specificity to target and capture all of the genes and their 5’ promoter and 3’ untranslated regions (UTRs).
The RainDance XSeq panel provides the industry’s leading coverage of the X-chromosome genes associated with the full range of complex X-linked disorders.
The RainDance XSeq™ Research Screening Panel Advantage
- Sequence all of the X Chromosome genes at the same time: Analyze greater than 98% of the genes and their exons fond on the human X chromosome in a single assay.
- Interrogate challenging regions of the genome: Examine all exons and both the 5’ promoter region and 3’ UTR for each gene, as well as repetitive sequences and regions of high sequence homology.
- Discover more disease causing mutations: Gain unprecedented single-base resolution of both common and rare genomic mutations associated with the human X chromosome.
- Eliminate traditional PCR bias: Single-molecule PCR ensures no competition between alleles, which reduces allelic dropout often associated with bulk PCR techniques.
- Optimize sequencer efficiency and increase sample throughput: Reduce amount and cost of downstream NGS required with greater amplification uniformity and enrichment specificity.
- Apply next-generation sequencing technology more routinely: Generate accurate, consistent and reproducible data at a fraction of the overall sample cost compared to existing Sanger sequencing methods.
- Accelerate time to results and simplify workflow: Leverage fully automated instrumentation and intuitive analysis workflow that produces PCR products in less than 1 hour and decreases overall hands-on time to less than 8 hours compared to multi-day hybridization-based sequence enrichment methods.
Comprehensive Content
The RainDance XSeq™ Research Screening Panel utilizes NGS technology to offer greater than 98% coverage from more than 800 genes encoded on the gene-rich human X chromosome. This includes more than 600 X-chromosome genes that have yet to be associated with a Mendelian disease, as well as all known Mendelian disorder genes. Coverage spans all exons and both the 5’ promoter region and 3’ UTR for each gene. A few of the more commonly sequenced genes represented in the XSeq panel include ALD, DMD, FMR1, F8 and GLA. With the XSeq panel, all of these can be sequenced together in a single powerful assay method.
*The RainDance XSeq™ Research Screening Panel is for research use only. Not for diagnostic purposes.
References
- Ross et al. (2005) The DNA sequence of the human X chromosome. Nature. Mar 17;434(7031):325-37.
- Tarpey et al. (2009) A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. May;41(5):535-43.
”For the first time, we have access to a cost-effective solution that allows us to use next-generation sequencing to simultaneously interrogate more than 1,000 genes on the X chromosome. This allows us to generate accurate, consistent and reproducible data at a fraction of the overall sample cost compared to previous sequencing methods.“
Michael Zwick, Ph.D., Assistant Professor, Emory University.
Press Release
